STM JOURNALS

Journal of
Polymer & Composites

ISSN: 2321-2810 (Online)
ISSN: 2321-8525 (Print)
Volume 13, Special Issue 6, 2025
DOI (Journal): 10.37591/JoPC

https://journals.stmjournals.com/jopc

Research JoPC

Biodegradable Polymer Nanocarriers Composites for Biomedical Applications

Kishor Waghulde[1,*], Nangare S. N.[2], G. G. Dongre[3], Shankar Lal Soni[4]

Abstract

Smart polymeric nanocarriers, or SPNs, have evolved into a fascinating means of delivering medications especially to cancer cells. By improving the efficacy of chemotherapeutic treatments while lowering their negative effects, they have achieved a significant progress in exact medicine. Made to respond to certain elements in the tumours microenvironment, such as enzymes, temperature, pH, and redox conditions, these nanocarriers this reaction to triggers guarantees the release of the medicine at the appropriate location, therefore improving its accessibility and reducing its systemic toxicity. Add different polymers poly (lactic-co-glycolic acid) (PLGA), polyethylene glycol (PEG), and dendrimers to SPNs to enable their correct release of medications and maintain stability. By interacting with overexpressed receptors and enhancing selectivity and absorption, adding ligands such as antibodies, peptides, small molecules allows one to target cancer cells. Apart from active targeting, passive targeting may also be accomplished by means of the enhanced permeability and retention (EPR) influence. This is the reason SPNs congregate in tumors leaky blood vessels. Together, passive and active targeting techniques have a synergistic impact that increases the efficacy of treatment even more. In the past few years, advanced nanotechnology methods like surface modification, packaging, and drug-loading optimisation have helped the development of SPNs. These methods make it easier to give many types of anticancer drugs, such as chemotherapy drugs, RNA-based treatments, and immunomodulatory drugs.

Keywords: Smart polymeric nanocarriers, targeted drug delivery, cancer therapy, stimuli-responsive, nanomedicine

INTRODUCTION

Cancer is still one of the main reasons of illness and death around the world, and standard treatments like surgery, radiation therapy, and chemotherapy often have serious side effects and don't work very well. Chemotherapy, in particular, kills cancer cells that divide quickly, but it also kills healthy cells, which can make people sick all over, weaken their immune systems, and loswer their quality of life. Traditional cancer treatments have some flaws that have led to the search for more accurate and powerful ways to treat the disease, especially ones that can improve drug targeting while reducing side effects. Use of smart polymeric nanocarriers (SPNs), which offer a new way to deliver drugs in cancer treatment, is one method that looks hopeful. Made from safe and recyclable polymers, smart polymeric nanocarriers are small structures able to contain therapeutic substances and release them in a targeted manner. Usually spanning 10 to 1000 nanometres, these nanocarriers are designed to

***Author for Correspondence**
Kishor Waghulde

[1]Assistant Professor, Department of Mechanical Engineering, Dr. D.Y. Patil Institute of Technology, Pimpri, Pune, Maharashtra, India
[2]Assistant Professor, Department of Pharmaceutics, Krishna Vishwa Vidyapeeth (Deemed to be University), Krishna Institute of Pharmacy, Karad, Maharashtra, India
[3]Assistant Professor, Department of Mechanical Engineering, Vishwakarma Institute of Technology, Pune, Maharashtra, India
[4]Assistant Professor, Department of Pharmacy, Arya College of Pharmacy, Jaipur, Rajasthan, India

Received Date: June 12, 2025
Accepted Date: July 22, 2025
Published Date: September 05, 2025

Citation: Kishor Waghulde, Nangare S. N., G. G. Dongre, Shankar Lal Soni. Biodegradable Polymer Nanocarriers Composites for Biomedical Applications. Journal of Polymer & Composites. 2025; 13(Special Issue 6): S293–S305p.

directly reach the cancer site where they may be released in response to certain triggers in the tumour microenvironment (TME). This precise release lowers any negative effects occurring elsewhere and increases the drug's effectiveness at its intended use. Since SPNs may be modified and used for different purposes, they are excellent for customised medication delivery. Treatment of cancer notably benefits from this. Using SPNs to treat cancer is based on their ability to use the variations between ordinary cells and tumours. Many times, physiological characteristics not typical of tumours change: an acidic pH, a greater temperature, and more concentrations of particular enzymes.

Furthermore commonly lacking organisation are the blood vessels in tumours, which may lead to weak blood vessels and a mechanism known as the enhanced permeability and retention (EPR) effect. This allows nanoparticles to collect predominantly in cancer tissue, acting as a passive targeting mechanism. Targeting ligands like antibodies, peptides, or small molecules helps SPNs to be even more focused. This allows one to deliberately target certain receptors connected to cancer [1]. Targeting both passively and actively, these concentrated nanocarriers ensure that medications reach cancer cells directly rather than into healthy tissues. The fact that SPNs may pass cellular obstacles that reduce the efficacy of conventional therapies is among their greatest advantages. For instance, because many medications cannot pass the blood-brain barrier (BBB), treating brain tumours becomes difficult. SPNs may be created, nevertheless, to pass the BBB. This allows sufferers with brain cancer and other neurological illnesses hope for a treatment because therapeutic medications reach the brain. To help them better penetrate cells, add medications, and release them, SPNs may also have their size and surface properties altered [2]. Developments in nanotechnology have made it simpler to produce nanocarriers capable of carrying a variety of compounds. Because they are biocompatible, biodegradable, and can store a multitude of different medicinal substances, they are often constructed from polymers such poly (lactic-co-glycolic acid) (PLGA), polyethylene glycol (PEG), polycaprolactone (PCL), and dendrimers. The polymers may be altered to provide various release patterns depending on the treatment requirements controlled, delayed, or triggered release. For instance, certain SPNs are designed to release their protein upon pH, temperature, or the presence of particular enzymes switched on in the TME change [3]. This guarantees that the medication is only released where it is needed, therefore reducing the danger of general poisoning even further. The ability of SPNs to provide a broad spectrum of healing agents is another advantage over conventional medication distribution systems. SPNs may provide biologics like monoclonal antibodies, nucleic acids (such as siRNA and mRNA), and immunotherapeutic medicines in addition to chemotherapeutic medications. Although they are unstable, not bioavailable, and might elicit immune system responses, these medications could result in more targeted and individualised therapies.

RELATED WORK

Many studies have proven that polymeric nanocarriers are beneficial in certain cancer therapy during the last few decades, and a lot of study has been done on the theory of employing nanocarriers to deliver medications. These investigations suggest that despite lowering their total effects, nanomedicine might be able to make anticancer medications more targeted, more bioavailable, and more effective. Among the most researched polymeric nanocarriers is Poly (lactic-co-glycolic acid), or PLGA. Its biodegradability, biocompatibility, and capacity to retain many different therapeutic compounds have attracted a lot of interest. Small compounds used in chemotherapy as well as biologics like siRNA and monoclonal antibodies have been carried on tiny PLGA particles [4]. By releasing them gradually and steadily at the tumours site, many experimental investigations have shown that PLGA nanoparticles may enhance the therapeutic efficacy of chemotherapy medicines such paclitaxel and doxorubicin. Furthermore, surface of PLGA nanoparticles may have receptors targeted on top of them to increase their specificity and enable cell absorption of the medicine. Another crucial contribution to the field is made by the polyethylene glycol (PEG)-based nanocarriers these are often utilised as they prolong the circulation of nanoparticles [5]. One of the main issues with using nanomedicines in medicine is that PEGylation of nanoparticles helps them escape being identified and thrown away by the immune system. Studies have shown via the enhanced permeability and retention (EPR) effect that PEGylated nanoparticles may improve the efficacy of chemotherapeutic medicines and enable their accumulation in cancer tissues.

Table 1. Summary of related work.

Related Work	Application	Future Trend	Limitation	Scope
Development of PLGA-based Nanocarriers	PLGA used for controlled release of chemotherapeutics	Use of biocompatible and biodegradable alternatives to PLGA	Challenges in scalability and uniform production of PLGA-based carriers	Enhance the clinical application of PLGA-based systems for chemotherapy
PEGylation of Nanoparticles [8]	PEG increases circulation time and reduces immune clearance	Development of PEG-free nanocarriers to avoid immune responses	PEGylation can lead to immune system recognition and clearance	Develop safer and more effective alternatives to PEGylation
Dendritic Polymers for Drug Delivery	Dendritic polymers offer high drug loading capacity and specificity	Integration of dendritic polymers with biomolecular therapies	Dendritic polymers can be expensive and complex to synthesize	Create dendritic polymers that can carry high payloads with minimal toxicity
Polymeric Micelles for Targeted Drug Delivery	Polymeric micelles used to enhance solubility and targeting	Optimization of polymeric micelles for dual-drug delivery	Polymeric micelles may have limited stability and high drug leakage	Expand the use of polymeric micelles in combination therapies
Stimuli-Responsive Nanocarriers [9]	pH, temperature, and enzyme-sensitive systems for tumor-specific drug release	Further development of stimuli-responsive nanocarriers for better selectivity	Stimuli-responsive systems can be sensitive to environmental changes	Improve the efficiency of stimuli-responsive systems for controlled release
Combination Therapy Using Nanocarriers	Nanocarriers that combine chemotherapy with gene or immunotherapy	Multi-functional nanocarriers combining therapies with imaging capabilities	Combination therapies may complicate production and regulatory approval	Advance multi-functional nanocarriers for personalized cancer treatment
Nanocarriers for Gene Therapy	Delivery of nucleic acids like siRNA or DNA	Gene editing and CRISPR delivery using nanocarriers	Gene therapy delivery faces challenges related to transfection efficiency	Advance the use of nanocarriers in genetic medicine and gene editing
Targeting Specific Tumor Antigens [10]	Ligand-based nanocarriers targeting overexpressed receptors on cancer cells	Precision targeting of tumors using personalized ligands	Ligand-targeting can be limited by receptor availability and heterogeneity	Improve precision in tumor targeting through advanced ligand design
Nanosystems for Brain Tumor Therapy	Nanocarriers engineered to cross the blood-brain barrier for brain tumor treatment	Design of smart nanocarriers for precise brain tumor targeting	Blood-brain barrier crossing remains difficult for large nanoparticles	Develop more effective nanocarriers for central nervous system tumors
Surface Functionalization with Peptides	Peptide-functionalized nanocarriers for receptor-mediated endocytosis	Increasing the specificity and efficiency of peptide-targeted drug delivery	Peptide-functionalized nanocarriers may exhibit poor pharmacokinetics	Enhance peptide-targeted nanocarriers to improve drug delivery precision
Nanocarriers for Delivery of Immunotherapeutic Agents	Nanocarriers delivering immune checkpoint inhibitors for cancer treatment	Integration of immunotherapy with nanocarrier-based delivery systems	Immunotherapy delivery is hindered by immune system interactions	Integrate nanocarriers with immunotherapies for synergistic cancer treatment
Nanocarriers for Chemotherapy Drug Delivery	Nanocarriers delivering conventional chemotherapy drugs to tumors	Advanced strategies to enhance drug release in tumor microenvironments	Chemotherapy drugs often result in off-target effects and toxicity	Develop safer and more effective drug delivery systems for chemotherapy
Nanocarriers for RNA and Protein Delivery [11]	Delivery of biologics (RNA, proteins) through polymeric nanoparticles	Innovative strategies for enhancing delivery of RNA and protein therapeutics	RNA/protein delivery requires stability in the bloodstream and efficient uptake	Explore the potential of RNA and protein therapeutics in personalized treatment

More research is under way, nevertheless, to identify the ideal PEGylation techniques for balancing immune system avoidance, drug loading, and release characteristics. Along with PLGA and PEG, dendritic polymers have also been explored as a means of delivering medications especially to cancer cells. These branching, very useful polymers allow you to control their size, shape, and surface properties. They are therefore ideal for surface functionalization and active targeting. Among other anticancer medications, gene therapies and chemotherapeutic agents have been carried on dendritic nanocarriers [6]. Increasing the effectiveness of chemo treatments may be possible thanks to their ability to hold large amounts of medicine and release them slowly. Researchers have also looked into stimuli-responsive polymeric nanocarriers, which release their medicinal content when pH, temperature, and enzyme activity change in the environment. The environment around a tumour is acidic, has a lot of enzymes, and changes temperatures, which makes it a great place for these smart nanocarriers to go. Researchers have shown that pH-sensitive and enzyme-triggered polymeric nanoparticles can release their cargo only at the tumour site, lowering the risk of systemic poisoning. For example, pH-sensitive polymeric micelles have been created to release drugs that are enclosed when they reach the acidic environment of tumours [7]. This makes the drug more effective at identifying and treating the tumour. In Table 1, linked work is summed up by pointing out uses, future trends, limits, and the area of study that needs to be done.

DEVELOPMENT OF SMART POLYMERIC NANOCARRIERS

Composition and properties of polymeric materials

Smart polymeric nanocarriers (SPNs) for specific drug transport depend on the make-up and qualities of the polymeric materials they are made of. Biodegradable and non-biodegradable polymers are the two main types of polymeric materials. Biodegradable polymers are better because they are biocompatible and can break down into harmless leftovers. Biodegradable polymers like poly (lactic-co-glycolic acid) (PLGA), polycaprolactone (PCL), and poly (lactic acid) (PLA) are often used in SPNs because they are biocompatible and easy to turn into nanoparticles. The choice of polymers for SPNs is based on a number of factors, such as how quickly they break down, how strong they are, and how much drug they can hold. Biodegradable plastics are especially helpful because they don't stay in the body for a long time and lower the risk of bad effects. One of the most studied polymers is PLGA because its breakdown rate can be changed [12]. This allows gradual release of healing chemicals over time. Furthermore influencing the release profile is the polymer's molecular weight. Higher molecular weight polymers often break down more slowly and deliver the medication over a longer length of time. Furthermore crucial for ensuring the medicine performs as expected are the surface properties of the polymer. Often utilised to alter the surface of SPNs so they may be employed in stealth environments is a hydrophilic substance known as polyethylene glycol (PEG) [13].

Design Principles for Targeting Mechanisms

Our main goal is to make sure that the drug only goes to the tumour and not to healthy cells. This will lower the risk of side effects and improve the effectiveness of the treatment. Passive targeting, which is based on the unique features of tumours, is one of the most common ways to target them. The blood vessels in tumours are disorganised and leaky, which lets nanoparticles slowly gather at the tumour site through the increased permeability and retention (EPR) effect [14]. This effect works best with SPNs that are between 10 and 200 nanometres in size. These particles are small enough to get into tumour tissue but big enough to stay in the bloodstream long enough to build up at the tumour site. Figure 1 shows some design rules for aiming systems that focus on making them accurate, flexible, and effective.

Active targeting methods can be added to SPNs to make them more specialised. To do this, targeted ligands are added to the polymeric surface so that they can bind to overexpressed receptors on the surface of cancer cells. Monoclonal antibodies, peptides, small molecules, and aptamers are all common targeting ligands. Some receptors or proteins that are more active in cancer cells are recognised by these ligands [15]. These include the epidermal growth factor receptor (EGFR), folate receptors, and integrins. SPNs can specifically interact with and enter cancer cells by connecting these targeting molecules to the polymeric nanocarriers.



Figure 1. Illustrating the design principles for targeting mechanisms.

This makes the therapy index higher. Some times, both passive and active targeting are used together to make drug delivery more accurate. Another interesting method is stimulus-responsive targeting, in which nanocarriers release their payload in reaction to pH, temperature, or chemical activity in the surroundings.

Synthesis and Characterization Techniques

Synthesising and characterising smart polymeric nanocarriers (SPNs) is important to make sure they work well, stay stable, and work with other drugs. There are several ways to make polymeric nanoparticles, and each has pros and cons that rely on the qualities of the nanocarrier that are wanted. Some of the most popular ways to make SPNs are through nanoprecipitation. This method dissolves a polymer in a solvent and then adds it to a non-solvent to make nanoparticles [16]. The liquid is then taken away, leaving behind nanoparticles with the medicine inside. Making uniformly sized nanoparticles with regulated drug release rates is made quite simple and reproducible by nanoprecipitation. Emulsion fluid evaporation is another frequent method that works particularly well for medications that dislike water. The polymer is blended with a watery phase including stabilisers and an organic solvent-based liquid. The polymeric nanoparticles follow from the removal of the organic liquid. This approach aims to produce highly drug-containing nanoparticles, although the stability of the drug will influence the encapsulating efficiency. Once produced, the nanocarriers must be characterised to ascertain their size, surface properties, drug-holding capacity, and release profiles [17]. Usually employed to determine the size of an SPN, dynamic light scattering (DLS) finds surface charge by use of zeta potential measurements. Shape of nanoparticles may be examined using scanning electron microscopy (SEM) or transmission electron microscopy (TEM). Usually, one finds the degree of drug encapsulation using high-performance liquid chromatography (HPLC) or UV-visible spectroscopy. Many times, in vitro drug release characteristics of SPNs are tested using dialysis [18]. This implies that the release of the medicine is seen over time under various pH levels resembling the microenvironment of a tumour.

MECHANISMS OF TARGETED DRUG DELIVERY

Passive targeting via the Enhanced Permeability and Retention (EPR) effect

Passive targeting is one of the most often used methods of delivering pharmaceuticals to certain regions as it makes sure that drugs only reach the correct locations by means of the physiologically-

based behaviour of tumours. The reason this approach works is the enhanced permeability and retention (EPR) effect. This impact makes use of the structure and working mechanism of tumour blood vessels. Often lacking organisation, blood arteries in tumours show larger and less consistent gaps between endothelial cells than in healthy tissues. These gaps allow nanoparticles, including smart polymeric nanocarriers (SPNs), to silently accumulate in the cancer tissue by bypassing the circulation. The EPR effect is made stronger by the fact that tumour cells usually don't drain lymphatic fluid well, which keeps nanoparticles inside the tumour for a longer time. Because of this, healing agents are more concentrated near the tumour, with less spreading throughout the body and harming healthy tissues [19]. Nanoparticles like liposomes, micelles, and dendrimers can all use the EPR effect for passive targeting, and not just polymeric nanocarriers. These nanomaterials can all build up at the site of the tumour. How well passive targeting works depends a lot on the nanoparticles' size and how they are coated. Nanoparticles with a diameter of 10 to 200 nm work best to use the EPR effect because they are small enough to get through leaky blood vessels but big enough to avoid being quickly cleared out by the mononuclear phagocytic system (MPS).

Active Targeting through Surface Modification

Active targeting is a way to improve the specificity of drug delivery by adding ligands to the surface of smart polymeric nanocarriers (SPNs) that can only interact with cancer cells that have overexpressed receptors or antigens. Instead of passive targeting, which only looks at how tumours are built, active targeting is a more direct and accurate way to get healing drugs to specific cancer cells. To change the surface of SPNs, specific molecules like monoclonal antibodies, peptides, aptamers, or small molecules are attached to them. These targeting ligands attach to certain antigens or receptors on cancer cells that are either overexpressed or only found in the tumour. Examples of these are EGFR, folate receptors, and integrins. This contact makes it easier for nanoparticles to enter cancer cells specifically through receptor-mediated endocytosis, which makes the drug much more effective. One of the best things about active targeting is that it can improve the sensitivity and specificity of the healing agent. This way, the drug can go straight to the cancer cells and not affect the healthy tissues. There is less chance of getting side effects like nausea, a weakened immune system, and hair loss that come with regular treatment. Active targeting and passive targeting can also be used together, which creates a more effective way to get drugs into tumour tissue through the EPR effect and interactions with specific receptors. Even though active targeting has a lot of promise, it also has some problems. For instance, targeting ligands may not always bind strongly to their receptors, which can make transport less effective. It is also important to think about how defence systems might get rid of functionalised nanoparticles, since changes to the surface can affect how well they work with living things and how long they stay in the bloodstream.

Stimuli-Responsive Release Mechanisms

Made to release their therapeutic payloads when certain environmental triggers are present in the tumour microenvironment (TME), responsive drug delivery systems are among these triggers include pH, temperature, enzyme activity, or the presence of certain compounds. Many times, these chemicals are associated with the terrible condition of cancer cells. Reacting to these types of triggers, smart polymeric nanocarriers (SPNs) may release medications in a targeted and under control manner. This gives them a more accurate and practical therapy alternative than conventional medication delivery systems. One of the most often employed components in medication release is the pH differential between normal and cancerous cells. While tumours are often more acidic with a pH of around 6.0 to 6.5, normal tissues have a pH of 7.4. Made to release their payload when they come into touch with the acidic conditions at the tumour site, polymeric nanocarriers sensitive to pH such as those derived from polymeric micelles or hydrogels are designed. Most of the time, these systems are made up of polymers that change shape or dissolve when the pH level changes. This lets the drug inside be released at the right place. Another type of material that responds to triggers is temperature-sensitive polymers. When compared to healthy tissues, tumours often have slightly higher temperatures. Nanocarriers that are sensitive to temperature are made to change phases at certain temperatures.

CHALLENGES AND FUTURE PERSPECTIVES

Current Limitations in Polymeric Nanocarrier Design

Smart polymeric nanocarriers (SPNs) have a lot of promise for specific drug delivery, but there are still some problems with how they are designed and how they are used. One of the main problems is making output scalable. It is well known how to make SPNs on a small scale in the lab, but it is still hard to make these nanocarriers on a big scale. On an industrial scale, it is still hard to make nanoparticles that are all the same size, have the same amount of drug, and have had their surfaces changed in the same way. Nanoparticles' different properties can change how well and consistently the drug transport system works, which can lead to varying treatment results. One more problem is that the materials used in nanocarrier design are not biocompatible and are harmful. Many polymers, like PLGA and PEG, are thought to be safe.

However, no one really knows what nanocarriers do to the body in the long run. Nanoparticles that build up in tissues that aren't supposed to have them can cause poisoning, immune reactions, or other unwanted side effects. Also, it's not always easy to guess how polymeric nanocarriers will be cleared from the body. Some of them may build up in organs like the liver or spleen, which could lead to long-term health problems. Making polymeric nanocarriers is also hard because they need to be stable and last a long time. The enclosed drugs, especially biologics like RNA or proteins, might break down while they are being stored or given. It is very important for the success of SPNs that both the carrier and the healing payload stay stable while they are being stored and when they are being used in the body. Lastly, relationships between defence systems can be very hard.

Advances in Nanotechnology and Material Science

Polymeric nanocarriers for specific medicine transport are changing because of progress in nanotechnology and material science. In particular, the creation of nanoparticles with better qualities has opened up new ways to make drug transport methods work better. One progress is the use of nanocomposites, which mix different types of materials (like organic polymers and metal nanoparticles) to make nanocarriers stronger, better at carrying drugs, and more stable. Figure 2 shows how advances in nanotechnology and material science have made medical and technological uses better.



Figure 2. Illustrating Advances in Nanotechnology & Material Science.

It looks like these mixed materials could help make the pharmacokinetics and release patterns of the drugs they hold better. Biodegradable and bioresponsive plastics have made it possible to make systems that are smarter and more focused. Polymers that react to pH, temperature, or enzyme activity in the tumour microenvironment (TME) make it possible to precisely control drug release. This makes sure that the healing agent gets to the tumour site where it needs to be. Polymer chemistry progress has also made it possible to change the surface qualities of nanoparticles.

Future Directions for Research and Clinical Practice

Future of smart polymeric nanocarriers (SPNs) in medication delivery is promising. Researchers are working hard to overcome current challenges and enable more precise and effective cancer therapy. One area of great interest is customising the way medications are given. Thanks to advances in genomic and proteomic screening, researchers can now more clearly see how the molecular patterns of every tumour vary. This information allows one to design SPNs especially targeted at certain genetic modifications or overexpressed receptors on cancer cells. This helps treatment to be more focused and successful. Personalised nanomedicine might drastically reduce the danger of adverse effects by a great degree and increase the likelihood of cancer therapies working. Another crucial route forward is combining therapies. Like cancer medicines, gene treatments, and immunotherapies, nanocarriers may transport many therapy agents. They are not constrained in terms of one medicine. By means of a single nanocarrier, various drugs might cooperate better, therefore improving the efficacy of therapies and overcoming issues such as drug resistance. For example, combining immune checkpoint inhibitors with chemotherapy on the same nanocarrier might strengthen the immune system while also more efficiently killing tumours.

RESULT AND DISCUSSION

Smart polymeric nanocarriers (SPNs) have shown a lot of promise in preliminary tests as a way to deliver specific drugs in cancer treatment. Both in vitro and in vivo tests show that SPNs can help drugs accumulate at tumour sites through inactive (EPR effect) and active (targeting ligands) processes, which improves the effectiveness of therapy. SPNs, like PLGA and PEG-modified nanoparticles, have been shown to effectively encapsulate chemotherapy drugs, making them more bioavailable and lowering their systemic toxicity. Nanocarriers that respond to stimuli have also been shown to release drugs in a controlled way based on the pH and enzyme activity of the tumour microenvironment.

Table 2 shows how well different polymeric materials used in nanocarrier design encapsulate drugs and how much drugs they can hold. Poly(lactic-co-glycolic acid), or PLGA, really does encapsulate drugs well—85% of the time. Figure 3 shows how drugs can be loaded and enclosed in polymers to allow controlled release in treatments.

This is why it is used so often in controlled drug delivery. However, it can only load 20% of a drug, which isn't very much. So, even though PLGA can effectively contain drugs, it might not be able to carry as many medicines per unit of nanocarrier.

PEG-PLGA, which is made up of PLGA and polyethylene glycol (PEG), works better than other materials because it can encapsulate drugs 90% of the time and hold 25% more drugs. Figure 4 shows how polymer packaging and filling methods are changing over time to make drug transport systems better. Adding PEG to the nanocarriers makes them more stable and extends their circulation time, which makes them perfect for delivering drugs to specific areas. PCL (Polycaprolactone) has a lower drug packaging efficiency of 75%. This might be because it breaks down more slowly. Its drug loading capacity of 18% is also smaller than most, which means it can't be used in formulas that need bigger doses.

Table 2. Drug encapsulation efficiency and drug loading capacity.

Polymeric Material	Drug Encapsulation Efficiency (%)	Drug Loading Capacity (%)
PLGA	85	20
PEG-PLGA	90	25
PCL	75	18
Dendritic Polymer	80	22



Figure 3. Drug Encapsulation & Loading in Polymers.



Figure 4. Encapsulation & loading trends in polymers.

Table 3. Size distribution and zeta potential of nanocarriers.

Polymeric Material	Average Size (nm)	Zeta Potential (mV)
PLGA	150	-20
PEG-PLGA	120	-15
PCL	180	-18
Dendritic Polymer	130	-22

Table 3 shows information about the size range and zeta potential of different types of polymeric nanocarriers. In general, PLGA is 150 nm wide and has a zeta potential of -20 mV. Its size is just right for delivering drugs effectively, so it can use the increased permeability and retention (EPR) effect. The average size of plastic materials changes in different situations, as shown in Figure 5.



Figure 5. Variation in Average Size of Polymeric Materials.

Table 4. In Vitro Drug Release Profile at Different pH.

Polymeric Material	Drug Release at pH 5.5 (%)	Drug Release at pH 7.4 (%)
PLGA	75	25
PEG-PLGA	80	20
PCL	65	30
Dendritic Polymer	70	28

But the zeta potential shows that it is only moderately stable, with the chance of clumping together or being recognised by the immune system. Because it is PEGylated, PEG-PLGA is more stable and has a smaller average size of 120 nm. This is because it has fewer interactions with cells that aren't specific. Its zeta potential of -15 mV means that it has less electrical repulsion than PLGA. This could mean that it has longer circulation times and less immune clearance, which makes it a good choice for specific treatments. Polycaprolactone (PCL) is 180 nm bigger than PCL, which might make it harder for it to get into smaller blood vessels or reach tumours.

In vitro drug release profiles of different polymeric materials are shown in Table 4. These profiles are shown at two pH levels: 5.5 (which is like the acidic environment inside a tumour) and 7.4 (which is the normal physiological pH). In Figure 6, drug release patterns at pH 5.5 and pH 7.4 are shown next to each other.

PLGA releases drugs more efficiently at pH 5.5 (75% of the time) than at pH 7.4 (25% of the time). This suggests that PLGA-based nanocarriers can adapt to the acidic conditions in tumours, making focused drug release easier. This trait helps get drugs to tumour sites more efficiently while reducing exposure to the rest of the body. PEG-PLGA also has a pH-dependent release profile, with 80% of the drug being released at pH 5.5 and 20% at pH 7.4. Figure 7 shows how drugs are released over time at different pH levels for controlled drug delivery.



Figure 6. Comparison of Drug Release at pH 5.5 and pH 7.4.



Figure 7. Cumulative Drug Release at Different pH Levels.

The slightly higher release at pH 5.5 compared to PLGA could be because PEGylation increases the carrier's permeability, which makes it more stable and better at targeting while keeping its pH-sensitive properties. Because PCL has a smaller release at both pH levels (65% at pH 5.5 and 30% at pH 7.4), it may not respond as well to the environment around the tumour as PLGA and PEG-PLGA. With a 70% drug release at pH 5.5 and a 28% drug release at pH 7.4, dendritic polymers have a measured reaction. This makes them useful for controlled drug distribution.

CONCLUSION

Smart polymeric nanocarriers (SPNs) have become an interesting way to deliver focused drugs in cancer therapy. They could make chemo treatments more specific and effective while reducing their side effects. Using the special features of the tumour microenvironment (TME), like the increased permeability and retention (EPR) effect, SPNs can gather in tumour cells more easily, which leads to better treatment results. Changing the surface with targeted molecules also makes it possible to actively target cancer cells, which improves the accuracy of drug transport even more. Adding stimuli-responsive materials lets healing agents be released under controlled conditions in reaction to certain external cues. This makes treatment more personalised. Polymeric materials like PLGA, PEG, and branching polymers are biocompatible, biodegradable, and flexible. These properties have made it easier to create SPNs that can carry a wide range of drugs, such as small molecules, proteins, and nucleic acids. These nanocarriers can be made to improve the metabolism of anticancer drugs, keep sensitive molecules from breaking down, and allow for steady or controlled release, which makes the beneficial action last longer. Even though SPN growth has come a long way, there are still some problems that need to be solved. Making a lot of nanocarriers that are all the same quality, good at encasing drugs, and stable is still a big problem that needs to be solved before they can be used in clinical settings. Also, making sure that nanoparticles are safe and will be cleared out in the long term, as well as avoiding any possible immune system interactions, needs careful optimisation. Also, the EPR effect works for many types of tumours, but it might not be enough for all of them. This means that more study is needed to find ways to make the effect more specific to tumours. Nanotechnology, material science, and polymer chemistry are all making progress that could help us solve these problems. To get the most out of SPNs in the field, future study will probably focus on how to combine tailored medicines, personalised medicine, and real-time tracking.

REFERENCES

1. Fazal T, Murtaza BN, Shah M, Iqbal S, Rehman MU, Jaber F, Dera AA, Awwad NS, Ibrahium HA. Recent developments in natural biopolymer based drug delivery systems. RSC advances. 2023;13(33):23087-121.
2. Alvi M, Yaqoob A, Rehman K, Shoaib SM, Akash MS. PLGA-based nanoparticles for the treatment of cancer: current strategies and perspectives. AAPS Open. 2022 Aug 1;8(1):12.
3. Braatz D, Cherri M, Tully M, Dimde M, Ma G, Mohammadifar E, Reisbeck F, Ahmadi V, Schirner M, Haag R. Chemical approaches to synthetic drug delivery systems for systemic applications. Angewandte Chemie International Edition. 2022 Dec 5;61(49):e202203942.
4. Gonçalves C, Ferreira N, Lourenço L. Production of low molecular weight chitosan and chitooligosaccharides (COS): A review. Polymers. 2021 Jul 27;13(15):2466.
5. Bashir SM, Ahmed Rather G, Patrício A, Haq Z, Sheikh AA, Shah MZ, Singh H, Khan AA, Imtiyaz S, Ahmad SB, Nabi S. Chitosan nanoparticles: a versatile platform for biomedical applications. Materials. 2022 Sep 20;15(19):6521.
6. Tian, B.; Hua, S.; Liu, J. Multi-functional chitosan-based nanoparticles for drug delivery: Recent advanced insight into cancer therapy. Carbohydr. Polym. 2023, 315, 120972.
7. Rostaminejad, B.; Dinari, M.; Karimi, A.R.; Hadizadeh, M. Oxidative cross-linking of biocompatible chitosan injectable hydrogel by perylene-dopamine to boost phototoxicity of perylene on in vitro melanoma and breast cancer therapy. J. Mol. Liq. 2023, 386, 122553.
8. Anirudhan, T.S.; Mohan, M.; Rajeev, M.R. Modified chitosan-hyaluronic acid based hydrogel for the pH-responsive Co-delivery of cisplatin and doxorubicin. Int. J. Biol. Macromol. 2022, 201, 378–388.
9. Kumar, K.; Rawat, S.G.; Manjit; Mishra, M.; Priya; Kumar, A.; Chawla, R. Dual targeting pH responsive chitosan nanoparticles for enhanced active cellular internalization of gemcitabine in non-small cell lung cancer. Int. J. Biol. Macromol. 2023, 249, 126057.
10. Liang, Y.; Wang, Y.; Wang, L.; Liang, Z.; Li, D.; Xu, X.; Chen, Y.; Yang, X.; Zhang, H.; Niu, H. Self-crosslinkable chitosan-hyaluronic acid dialdehyde nanoparticles for CD44-targeted siRNA delivery to treat bladder cancer. Bioact. Mater. 2021, 6, 433–446.

11. Abhijeet Bhowmik, Dilip Mishra . (2016). A Comprehensive Study of an Aluminum Alloy AL-5052. Advance Physics Letter, 3(1), 20-22.
12. Neha Verma, Rityuj Singh Parihar. (2016). APPLICATION OF SIX SIGMA TOOL (DMAIC). Advance Physics Letter, 3(2), 1-3.
13. Escareño, N.; Hassan, N.; Kogan, M.J.; Juárez, J.; Topete, A.; Daneri-Navarro, A. Microfluidics-assisted conjugation of chitosan-coated polymeric nanoparticles with antibodies: Significance in drug release, uptake, and cytotoxicity in breast cancer cells. J. Colloid Interface Sci. 2021, 591, 440–450.
14. Bhattacharyya, M.; Jariyal, H.; Srivastava, A. Hyaluronic acid: More than a carrier, having an overpowering extracellular and intracellular impact on cancer. Carbohydr. Polym. 2023, 317, 121081.
15. Yasin, A.; Ren, Y.; Li, J.; Sheng, Y.; Cao, C.; Zhang, K. Advances in hyaluronic acid for biomedical applications. Front. Bioeng. Biotechnol. 2022, 10, 910290.
16. Hou, X.; Zhong, D.; Chen, H.; Gu, Z.; Gong, Q.; Ma, X.; Zhang, H.; Zhu, H.; Luo, K. Recent advances in hyaluronic acid-based nanomedicines: Preparation and application in cancer therapy. Carbohydr. Polym. 2022, 292, 119662.
17. Hejazi, M.; Arshadi, S.; Amini, M.; Baradaran, B.; Shahbazi-Derakhshi, P.; Sameti, P.; Soleymani, J.; Mokhtarzadeh, A.; Tavangar, S.M. Hyaluronic acid-functionalized gold nanoparticles as a cancer diagnostic probe for targeted bioimaging applications. Microchem. J. 2023, 193, 108953.
18. Maki, M.A.A.; Teng, M.S.; Tan, K.F.; Kumar, P.V. Polyamidoamine-stabilized and hyaluronic acid-functionalized gold nanoparticles for cancer therapy. OpenNano 2023, 13, 100182.
19. Michalczyk, M.; Humeniuk, E.; Adamczuk, G.; Korga-Plewko, A. Hyaluronic Acid as a Modern Approach in Anticancer Therapy-Review. Int. J. Mol. Sci. 2022, 24, 103.

